Related Experiment Video
Updated: Oct 24, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.1K
Biological therapy for severe asthma.
Silvano Dragonieri1, Giovanna Elisiana Carpagnano2
1Department of Respiratory Diseases, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124, Bari, Italy. silvano.dragonieri@uniba.it.
Asthma Research and Practice
|August 14, 2021
Summary
Severe asthma affects 5-10% of patients, but new biologic therapies offer significant benefits. This review helps physicians select the best biologic treatment for severe asthma based on biomarkers.
Area of Science:
- Pulmonology
- Immunology
- Pharmacology
Background:
- Severe or uncontrolled asthma impacts 5-10% of asthmatics, leading to higher mortality, hospitalizations, and reduced quality of life.
- Recent advancements include identifying distinct asthma phenotypes and developing targeted biologic therapies.
Purpose of the Study:
- To review currently available biologic therapies for severe asthma.
- To aid physicians in selecting the most appropriate biologic agent for individual patients.
Main Methods:
- Literature review of licensed biologic therapies for severe asthma.
- Analysis of biologic mechanisms targeting specific asthma biomarkers.
Main Results:
- Four classes of biologics are approved: anti-immunoglobulin E (omalizumab), anti-interleukin-5 (mepolizumab, reslizumab), anti-interleukin-5 receptor alpha (benralizumab), and anti-interleukin-4 receptor alpha (dupilumab).
- Biologic therapies have shown high efficacy and significant clinical benefits in managing severe asthma.
Conclusions:
- Biologics have transformed severe asthma management.
- Personalized treatment selection based on biomarkers is crucial for optimizing patient outcomes.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
860
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
860
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
718
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
718
01:26Asthma-II: Pathophysiology and Classification
3.4K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.4K
01:19Antiasthma Drugs: Leukotriene Modifiers
723
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
723
01:30Asthma-IV: Diagnostic and Management
2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
654
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
654